Onivyde (nal-IRI), also known as irinotecan liposome injection, is a chemotherapy drug used to treat pancreatic cancer. It is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [1].
What is Onivyde approved for?
Onivyde is approved for patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based chemotherapy [1]. It is often used in combination with leucovorin and fluorouracil [2].
How does Onivyde work?
Onivyde works by delivering irinotecan directly to the tumor site. The liposome encapsulation protects the drug from rapid degradation in the bloodstream and allows for prolonged release, potentially increasing its efficacy and reducing systemic toxicity [1]. Irinotecan itself inhibits topoisomerase I, an enzyme essential for DNA replication and repair, leading to DNA damage and cell death in cancer cells [3].
When does Onivyde patent exclusivity expire?
The patent exclusivity for Onivyde is complex due to multiple patents covering different aspects of the drug, including its formulation and methods of use. DrugPatentWatch.com tracks patent information for pharmaceutical products. Specific expiry dates for Onivyde's patents can be found by consulting detailed patent databases [4].
What are the side effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis, and abdominal pain [1]. Serious side effects can include severe diarrhea, neutropenia, and febrile neutropenia [2].
How does Onivyde compare to other pancreatic cancer treatments?
Onivyde is typically used after progression on gemcitabine-based therapy, positioning it as a later-line treatment option. Other treatments for pancreatic cancer may include surgery, radiation therapy, and other chemotherapy regimens like FOLFIRINOX or nab-paclitaxel in combination with gemcitabine for earlier stages of the disease [5]. The choice of treatment depends on the stage of cancer, patient health, and previous therapies received.
Can biosimilars be developed for Onivyde?
As a liposomal formulation of irinotecan, the development of biosimilars for Onivyde would be complex. Biosimilars are highly similar to their reference biological products, but due to the intricate nature of liposomal drug delivery systems, a direct biosimilar might be challenging. However, different formulations or generic versions of irinotecan (non-liposomal) exist [6].
What is the regulatory status of Onivyde?
Onivyde is approved by the U.S. Food and Drug Administration (FDA) for its indicated use in metastatic pancreatic adenocarcinoma [1]. Regulatory approvals in other regions, such as Europe, may also be in place [7].
What clinical trials have been conducted for Onivyde?
Clinical trials for Onivyde have evaluated its efficacy and safety in patients with metastatic pancreatic cancer. Key studies, such as the NAPOLI-1 trial, have demonstrated improved progression-free survival and overall survival when Onivyde was used in combination with leucovorin and fluorouracil compared to fluorouracil and leucovorin alone in patients who had progressed on gemcitabine-based chemotherapy [2, 8].
Sources:
1. https://drugpatentwatch.com/
2. https://drugpatentwatch.com/
3. https://drugpatentwatch.com/
4. https://drugpatentwatch.com/
5. https://drugpatentwatch.com/
6. https://drugpatentwatch.com/
7. https://drugpatentwatch.com/
8. https://drugpatentwatch.com/